Barnes D, Hughes RAC, Morris RW, et al: Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349:902, 1997.
Barnett MH, Prineas JW: Relapsing and remitting multiple sclerosis. Pathology of the newly forming plaque. Ann Neurol 55:458, 2004.
Beck RW, Chandler DL, Cole SR, et al: Interferon β-1a for early multiple sclerosis: CHAMPS trial subgroup analysis. Ann Neurol 51:481, 2002.
Beck RW, Cleary PA, Anderson MM Jr, et al: A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326:581, 1992.
Beck RW, Trobe JD, Moke PS, et al: Highand low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: Experience of the optic neuritis treatment trial. Arch Ophthalmol 121:944, 2003.
Beebe GW, Kurtzke JF, Kurland LT, et al: Studies on the natural history of multiple sclerosis: 3. Epidemiologic analyses of the Army experience in World War II. Neurology 17:1, 1967.
Birk K, Rudick R: Pregnancy and multiple sclerosis. Arch Neurol 43:719, 1986.
Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870, 2012.
Bobholz JA, Rao SM: Cognitive dysfunction in multiple sclerosis: A review of recent developments. Curr Opin Neurol 16:283, 2003.
Bot JC, Barkhof F, Polman CH, et al: Spinal cord abnormalities in recently diagnosed MS patients. Added value of spinal MRI examination. Neurology 62:226, 2004.
British and Dutch Multiple Sclerosis Azathioprine Trial Group: Double masked trial of azathioprine in multiple sclerosis.
Lancet ii:179, 1988.
CAMMS223 Trial Investigators et al: A randomized, rater-blinded, trial of alemtuzumab versus interferon beta-1a in early, relapsing remitting multiple sclerosis. N Engl J Med 359:1786, 2008.
CHAMPS Study Group: Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 132:463, 2001.
Cohen JA, Barkhof F, Comi G, et al; TRANSFORMS Study Group: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402, 2010.
Cohen JA, Coles AJ, Arnold DL, et al: Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 380:1819, 2012.
Collongues N, de Seze J: Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord 4:111, 2011.
Compston A, Confavreux C: The distribution of multiple sclerosis. In: Compston A, Lassman H, McDonald I, et al (eds):
McAlpine’s Multiple Sclerosis, 4th ed. New York, Churchill